PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan et al., 2013
Neurological & CognitiveInvestigational (Phase 2)S
ARA-290
Cibinetide
Non-erythropoietic peptide studied for neuropathic and inflammatory indications.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- S
- Community score
- 233
- Trackers
- 4,868
Trend index
Overview
About ARA-290
Non-erythropoietic peptide studied for neuropathic and inflammatory indications.
- Category
- Neurological & Cognitive
- Regulatory status
- Investigational (Phase 2)
- Also known as
- Cibinetide
- Self-reports
- 6
Community
What 6 users report
6 community reports
Positive 33% · Neutral 67% · Negative 0%
Most reported benefits
Appetite
6
Most reported side effects
Injection site irritation
4
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
6
Commonly stacked with
Research
Cited research (1)
Source
Help
Frequently asked
What do PeptIQ users report about ARA-290?
This page summarizes 6 anonymized self-reports from PeptIQ users who track ARA-290, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for ARA-290?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is ARA-290 safe to use?
This wiki does not assess safety or recommend use. ARA-290 is listed as Investigational (Phase 2). Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of ARA-290?
Research, primarily in animal models, suggests ARA-290 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of ARA-290?
ARA-290 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified ARA-290 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of ARA-290?
The safety and effectiveness of ARA-290 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on ARA-290?
While there are over 200 published studies on ARA-290, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source